RekrutujeFaza I
An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis
Miasta: Bydgoszcz, Lublin, Nowy Targ, Pabianice i 5 innych miastWiek: 18-64 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza II/III
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Bytom, Kraków, Lublin i 11 innych miastWiek: od 18 latSponsor: Janssen Cilag International
RekrutujeFaza II
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Miasta: Bydgoszcz, Chojnice, Grudziądz, Katowice i 10 innych miastWiek: od 18 latSponsor: Genentech Inc.
RekrutujeFaza III
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Miasta: Białystok, Bydgoszcz, Chojnice, Karczew i 16 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza II
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Miasta: Bydgoszcz, Bytom, Kalisz, Katowice i 17 innych miastWiek: od 18 latSponsor: Abivax